Sub-Classification of Lateral Cervical Lymph Node @entity3 in XXXX by Pathologic Criteria.

@entity3557 @entity1 @entity5 @entity3
BACKGROUND: Lateral cervical lymph node (LCLN) @entity3 , or pathologic N1b disease, is an important risk factor in @entity3557 ( @entity3557 ). However, many @entity1 have favorable prognosis even with pathologic N1b @entity1 in clinical practice. The study aims to identify high- and intermediate-risk groups based on initial pathologic characteristics in these @entity1 . @entity1 : This study included 518 classical @entity3557 @entity1 confirmed as pathologic N1b at initial surgery between 2001 and 2010. All @entity1 underwent a single fixed activity (5.6 GBq) of radioactive I-131 remnant ablation. RESULTS: @entity1 with a @entity5 larger than 4 cm, gross extrathyroidal extension, metastatic LN larger than 3 cm, or greater than 10 metastatic LCLN were classified as high-risk group. These comprehensive pathologic criteria were retrieved from cox proportional hazard models. Twenty two percent of @entity1 (n = 113) were classified as high-risk and 78% (n = 405) as intermediate-risk group. Successful ablation was identified in only 32% of the @entity1 in the high-risk group and 61% in the intermediate-risk group (p < 0.001). The difference between the two risk groups was independent to gender. There was a significant difference in disease-free survival between the high- and intermediate- risk N1b groups during 5.1 years of median follow-up (84% vs. 59%, p < 0.001). Distant @entity3 was more prevalent in the high-risk group (20%) than in the intermediate-risk group (4%, p < 0.001). CONCLUSIONS: The prognosis of @entity3557 @entity1 with LCLN @entity3 varies depending on initial pathologic characteristics. We proposed the comprehensive pathologic criteria for sub-classification of N1b into high- and intermediate-risk groups and this sub-classification may permit personalized management of N1b @entity3557 @entity1 .
